167 related articles for article (PubMed ID: 30089901)
1. High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review.
Varga C; Comenzo RL
Bone Marrow Transplant; 2019 Apr; 54(4):508-518. PubMed ID: 30089901
[TBL] [Abstract][Full Text] [Related]
2. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
[TBL] [Abstract][Full Text] [Related]
3. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
4. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.
Sanchorawala V; Boccadoro M; Gertz M; Hegenbart U; Kastritis E; Landau H; Mollee P; Wechalekar A; Palladini G
Amyloid; 2022 Mar; 29(1):1-7. PubMed ID: 34783272
[TBL] [Abstract][Full Text] [Related]
6. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.
Landau H; Smith M; Landry C; Chou JF; Devlin SM; Hassoun H; Bello C; Giralt S; Comenzo RL
Leukemia; 2017 Jan; 31(1):136-142. PubMed ID: 27560108
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
[TBL] [Abstract][Full Text] [Related]
8. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
9. High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis.
Sanchorawala V
Acta Haematol; 2020; 143(4):381-387. PubMed ID: 32248194
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Wolf RC; Kumar SK; Gertz MA
Bone Marrow Transplant; 2019 Jul; 54(7):1077-1081. PubMed ID: 30390060
[TBL] [Abstract][Full Text] [Related]
11. High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators.
Phull P; Sanchorawala V; Brauneis D; Sloan JM; Siddiqi OK; Quillen K; Sarosiek S
Bone Marrow Transplant; 2019 Aug; 54(8):1304-1309. PubMed ID: 30664726
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.
Lee SY; Sanchorawala V; Seldin DC; Mark Sloan J; Andrea N; Quillen K
Amyloid; 2014 Sep; 21(3):149-53. PubMed ID: 24779777
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
[TBL] [Abstract][Full Text] [Related]
14. Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis.
Freeman B; Brauneis D; Seldin DC; Quillen K; Sloan JM; Renteria AS; Shelton AC; Teschner T; Finn KT; Sanchorawala V
Bone Marrow Transplant; 2014 Oct; 49(10):1345-6. PubMed ID: 24955784
[No Abstract] [Full Text] [Related]
15. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
[TBL] [Abstract][Full Text] [Related]
16. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
[TBL] [Abstract][Full Text] [Related]
17. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
Taimur S; Nader C; Lloyd-Travaglini C; Seldin DC; Sanchorawala V
Transpl Infect Dis; 2013 Apr; 15(2):187-94. PubMed ID: 23279695
[TBL] [Abstract][Full Text] [Related]
18. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.
Sanchorawala V
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1131-44. PubMed ID: 25459183
[TBL] [Abstract][Full Text] [Related]
19. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
20. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
Gertz MA; Lacy MQ; Dispenzieri A; Buadi FK; Dingli D; Hayman SR; Kumar SK; Leung N; Lust J; Rajkumar SV; Russell SJ; Suman VJ; Le-Rademacher JG; Hogan WJ
Cancer; 2016 Jul; 122(14):2197-205. PubMed ID: 27142462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]